AFM
ROSG

Anson Funds Management’s Rosetta Genomics Ltd. ROSG Stock Holding History

Anson Funds Management’s Portfolio ROSG Stock Details ROSG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-22,879
Closed -$338K – 103
2015
Q4 		$338K Buy
+22,879
New +$494K 0.11% 55
2015
Q1 		– Sell
-7,168
Closed -$194K – 83
2014
Q4 		$194K Buy
+7,168
New +$233K 0.23% 44

Other funds holding ROSG

HCM
Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ICAS
Investors Capital Advisory Services Lynnfield, Massachusetts $521M AUM 1.51% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Anson Funds Management's ROSG Position: Q1 2016 in Review

Anson Funds Management sold out of Rosetta Genomics Ltd. (ROSG) in Q1 2016, closing a stake of 22,879 shares — an estimated $338K sold.

Anson Funds Management first reported a position in ROSG in Q4 2014 and held it in 2 quarters. The position peaked at $338K in Q4 2015. 10 funds tracked by Wall St. Rank hold ROSG as of Q1 2016.

  • Anson Funds Management reported no remaining Rosetta Genomics Ltd. position as of Q1 2016 after selling out during the quarter.
  • Anson Funds Management sold 22,879 Rosetta Genomics Ltd. shares in Q1 2016, an estimated $338K.
  • Anson Funds Management first reported a position in Rosetta Genomics Ltd. in Q4 2014 and held it in 2 quarters.
  • Anson Funds Management's Rosetta Genomics Ltd. position peaked at $338K in Q4 2015.
  • 10 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q1 2016.

Based on Anson Funds Management's 13F filing for Q1 2016, filed 13 May 2016.